This phase 1-2 trial demonstrates that delpacibart etedesiran (del-desiran), an innovative antibody-oligonucleotide conjugate, effectively reduces toxic DMPK mRNA and ameliorates missplicing in patients with Myotonic Dystrophy Type 1, marking a potential breakthrough for a disease with no current approved therapies.